Key facts
- Phenomix Sciences’s last known valuation is $32.5M (Dec 2025).
- It has raised $10.4M across 1 recorded rounds; the latest was Seed Round ($1.1M) in May 2018.
- Notable investors include National Institutes of Health, Labcorp Venture Fund, Mayo Clinic, DexCom, Health2047 — 10 tracked in total.
- Phenomix Sciences has filed 1 Form D with the SEC, most recently Jan 2020 ($1.1M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Phenomix Sciences
Funding rounds
1 roundsAbout Phenomix Sciences
Developer of a data analysis platform designed for precision medicinal research on obesity management. The company's platform offers a novel blood test supported by an AI-driven algorithm that classifies the unique pathophysiological phenotype of patients with obesity, enabling healthcare centers to get precision medicine tools and services that change obesity management with efficacy and fewer side effects.
- Sector
- Healthcare
- HQ
- Wayzata, MN, United States
- Founded
- 2017
- Employees
- 9
- Website
- phenomixsciences.com/
- Ownership
- Privately Held (backing)
Phenomix Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phenomix Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phenomix Sciences in its N-PORT filings yet. We sweep new filings monthly.